N-acetylcysteine Reduces Acetaldehyde Levels in Binge Alcohol Drinking

Sponsor
University Medical Centre Ljubljana (Other)
Overall Status
Completed
CT.gov ID
NCT05911282
Collaborator
(none)
40
1
2
29
42

Study Details

Study Description

Brief Summary

Alcohol hangover (veisalgia) is a fairly common phenomenon. The pathogenesis of veisalgia is not understood and treatment has not yet been established. Occasionally, students take N-acetylcysteine (NAC) before binge drinking to alleviate hangover. The aim of the study was to evaluate the effect of NAC on serum levels of electrolytes, enzymes, acetaldehyde, oxidative stress biomarkers and symptoms of veisalgia in binge drinking. In this randomised double-blind placebo-controlled study, healthy students were randomly assigned into two groups, one receiving NAC and the other placebo. Blood samples were taken before drinking, 30 minutes after 1.5-hour-long drinking and in the subsequent morning. Serum levels of electrolytes, urea, enzymes, ethanol, acetaldehyde, 8-Hydroxydeoxyguanosine (8-OHdG) and N-epsilon-hexanoyl-lysine were measured. The participants completed the Acute Hangover Severity Scale (AHSS) based on symptoms.

Condition or Disease Intervention/Treatment Phase
  • Drug: N Acetylcysteine
  • Other: Lemon juice
N/A

Detailed Description

On the study day, the participants met at the study location with the investigator at 6.pm. In the beginning they all ate two pizza slices. They filled out a pre-drinking evaluation form about veisalgia (score 1 - 10) and specific symptoms (score 1 - 10). They performed a breath alcohol test with Dräger Alcotest 6820 to exclude volunteers who had been drinking before the study. The registered nurses took blood samples before drinking.

Volunteers were randomly assigned into two groups, one receiving NAC (1.2 g before and 1.2 g after drinking alcohol), and the other placebo. Each participant received an identification number, randomisation was done by a computer. The study began at 7 pm, when they drank the contents of a numbered cup with NAC or placebo corresponding to their number. The researchers and volunteers on the scene were not aware which cups contain NAC or placebo. Afterwards they drank 40 %, v/v, gin mixed with tonic according to the participant's preferences. The drinking was calm. They were mostly sitting and did not participate in any physical activity such as dancing. No other legal or illegal substances or medications were taken during the study.

The drinking ended at 8.30 pm. The nurses took the second blood sample 30 minutes after 1.5-hour-long drinking. The volunteers also performed the second breath alcohol test.

At 9 pm, they were given the second cup with 1.2 g of NAC or placebo corresponding to their randomized number. The latest one hour after the second blood sample was taken all the participants went to sleep.

In the next morning at 6 am (9 hours after drinking) the third blood sample was taken in all volunteers. They performed the third breath alcohol test and filled out a post-drinking form about veisalgia (score 1 - 10), specific symptoms (score 1 - 10), and Alcohol Hangover Severity Scale (AHSS).

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
N-acetylcysteine Reduces Acetaldehyde Levels in Binge Alcohol Drinking
Actual Study Start Date :
Jun 1, 2021
Actual Primary Completion Date :
Jun 30, 2021
Actual Study Completion Date :
Jun 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: NAC

NAC group was given 1.2 g of N-acetylcysteine before and 1.2 g after drinking alcohol

Drug: N Acetylcysteine
The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number. The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study.
Other Names:
  • NAC
  • Placebo Comparator: PLACEBO

    Placebo group was given lemon juice before and after drinking alcohol

    Other: Lemon juice
    The study began at 7 pm, when the volunteers in placebo group drank the contents of a numbered cup with lemon juice. At 9 pm, they were given the second cup with lemon juice corresponding to their randomized number. The cups with lemon juice were prepared and numbered by the physician not attending the drinking just before the study.
    Other Names:
  • placebo
  • Outcome Measures

    Primary Outcome Measures

    1. Alcohol Hangover Severity Scale [next morning after drinking (at 6 am; 9 hours after drinking)]

      In the next morning after drinking (at 6 am; 9 hours after drinking) the volunteers filled out a standardised questionnaire Alcohol Hangover Severity Scale (AHSS), which includes twelve symptoms correlating with veisalgia: palpitation, sweating, confusion, apathy, abdominal pain, shivering, dizziness, nausea, clumsiness, concentration problems, thirst and fatigue. Every symptom was graded on the scale from 0 to 10 points, where 0 point meant the absence of the symptom and 10 points the extreme severity of the symptom. The result of the AHSS questionnaire was calculated for every participant as the average number of points from all of the 12 symptoms (minimum average value was 0 points and maximum 10 points).

    2. Change in acetaldehyde level after drinking compared to the baseline value [before drinking (at 7 pm), within 30 minutes after 1.5 hour long drinking (at 9 pm) and in the next morning after drinking (at 6 am, 9 hours after drinking)]

      Quantification of acetaldehyde in blood samples

    3. Change in serum oxidative biomarker level after drinking compared to the baseline value [before drinking (at 7 pm), within 30 minutes after 1.5 hour long drinking (at 9 pm) and in the next morning after drinking (at 6 am, 9 hours after drinking)]

      Quantification of 8-Hydroxydeoxyguanosine and N-epsilon-hexanoyl-lysin in blood samples

    Secondary Outcome Measures

    1. Change in serum ethanol level after drinking compared to the baseline value [before drinking (at 7 pm), within 30 minutes after 1.5 hour long drinking (at 9 pm) and in the next morning after drinking (at 6 am, 9 hours after drinking)]

      Quantification of ethanol in blood samples

    2. Change in serum sodium levels after drinking compared to the baseline [before drinking (at 7 pm), within 30 minutes after 1.5 hour long drinking (at 9 pm) and in the next morning after drinking (at 6 am, 9 hours after drinking)]

      Quantification of serum sodium in blood samples

    3. Change in serum potassium levels after drinking compared to the baseline [before drinking (at 7 pm), within 30 minutes after 1.5 hour long drinking (at 9 pm) and in the next morning after drinking (at 6 am, 9 hours after drinking)]

      Quantification of serum potassium in blood samples

    4. Change in serum urea levels after drinking compared to the baseline [before drinking (at 7 pm), within 30 minutes after 1.5 hour long drinking (at 9 pm) and in the next morning after drinking (at 6 am, 9 hours after drinking)]

      Quantification of serum urea in blood samples

    5. Change in serum creatinine levels after drinking compared to the baseline [before drinking (at 7 pm), within 30 minutes after 1.5 hour long drinking (at 9 pm) and in the next morning after drinking (at 6 am, 9 hours after drinking)]

      Quantification of serum creatinine in blood samples

    6. Change in serum creatinine kinase levels after drinking compared to the baseline [before drinking (at 7 pm), within 30 minutes after 1.5 hour long drinking (at 9 pm) and in the next morning after drinking (at 6 am, 9 hours after drinking)]

      Quantification of serum creatinine kinase in blood samples

    7. Change in serum lactate dehydrogenase levels after drinking compared to the baseline [before drinking (at 7 pm), within 30 minutes after 1.5 hour long drinking (at 9 pm) and in the next morning after drinking (at 6 am, 9 hours after drinking)]

      Quantification of serum lactate dehydrogenase in blood samples

    8. Change in serum aspartate and alanine aminotransferase levels after drinking compared to the baseline [before drinking (at 7 pm), within 30 minutes after 1.5 hour long drinking (at 9 pm) and in the next morning after drinking (at 6 am, 9 hours after drinking)]

      Quantification of serum aspartate and alanine aminotransferase in blood samples

    9. Change in serum gamma glutamyl transferase levels after drinking compared to the baseline [before drinking (at 7 pm), within 30 minutes after 1.5 hour long drinking (at 9 pm) and in the next morning after drinking (at 6 am, 9 hours after drinking)]

      Quantification of serum gamma glutamyl transferase in blood samples

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • medical students, who regularly attend social gatherings where alcohol is consumed and had already experienced the symptoms of hangover.

    • healthy

    • not pregnant

    • without any chronic diseases

    • not taking any medications.

    • signed informed consent.

    Exclusion Criteria:
    • drinking after the end of the study

    • taking any other psychoactive substances or took other measures that supposedly could alleviate the hangover symptoms

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Medical Centre Ljubljana Ljubljana Slovenia 1000

    Sponsors and Collaborators

    • University Medical Centre Ljubljana

    Investigators

    • Principal Investigator: Miran Brvar, MD, University Medical Centre Ljubljana

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Miran Brvar, Head of Centre for Clinical Toxicology and Pharmacology, University Medical Centre Ljubljana
    ClinicalTrials.gov Identifier:
    NCT05911282
    Other Study ID Numbers:
    • 20200175
    First Posted:
    Jun 22, 2023
    Last Update Posted:
    Jun 22, 2023
    Last Verified:
    Jun 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 22, 2023